BioSpace News Archive

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer will present at the upcoming LD Micro Main Event Investor Conference being held from December 10-12, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s elio™ tissue complete assay in a Merck trial of pembrolizumab-based combination therapy.

Grant seeks to support patient-centric research through funding and access to real-world oncology datasets

Biocon Biologics, a fully integrated ‘pure play’ global biosimilars organisation, is taking forward its mission of unlocking affordable access to quality insulins for people with diabetes across the world.

Noblegen’s protein-rich euglena flour will be available to the US market immediately.

Product sales through Biossance.com have been comprising a greater portion of sales channel mix and these sales deliver much higher margins.

This is the first patent issued protecting the method of use for the dipeptidase-1 (DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th Annual LD Micro Main Event investor conference.

New basic and preclinical research laboratory at the INRS Center Armand-Frappier Health Biotechnology in Laval, Quebec.

Dr. Paskavitz has over fifteen prior years of clinical experience including outpatient treatment of neurodegenerative diseases and inpatient intensive care neurology.